Core Viewpoint - Polyrizon Ltd. has received approval from the Nasdaq Hearings Panel to continue its listing on the Nasdaq Capital Market, following a plan to address concerns regarding its capital structure and compliance with listing standards [1][3]. Group 1: Nasdaq Listing and Compliance - The Nasdaq Listing Qualifications Department previously issued a public interest determination under Listing Rule 5101 due to the company's issuance of securities in a private placement, particularly concerning Series A warrants [2]. - A hearing was held on June 26, 2025, where Polyrizon presented its plan to avoid complex financing instruments in future capital-raising activities [3]. - The Panel's determination on July 9, 2025, allows the company to maintain its listing, contingent upon regaining compliance with the Minimum Bid Price Rule by October 17, 2025 [3]. Group 2: Financial Position and Capital Structure - Following the private placement, the company reported a cash balance of approximately $15.68 million, and all warrants issued in the transaction have been exercised, simplifying its capital structure [4]. - The elimination of a significant source of potential dilution is expected to enhance long-term shareholder value [4]. Group 3: Internal Controls and Future Plans - The company is implementing a formal internal control framework to govern future securities issuances and ensure compliance with Nasdaq standards, including enhanced oversight and quarterly internal compliance reviews [5]. Group 4: Company Overview - Polyrizon is a development stage biotech company focused on innovative intranasal hydrogels that create a barrier against viruses and allergens in the nasal cavity [5]. - The proprietary Capture and Contain hydrogel technology is designed to function as a "biological mask," and the company is also developing the Trap and Target technology for nasal delivery of active pharmaceutical ingredients [5].

BASEL, Switzerland and SEOUL, South Korea, July 15, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr Andreas Niethammer, M.D., Ph.D., as Chief Medical Officer of Vaximm AG, an OSR Company developing a platform of orally administered target-specific T-cell activators, including VXM01, a clinical stage anti-VEGFR-2. . OSR Holdi ...

Core Insights - BriaCell Therapeutics Corp. has added Mayo Clinic as a key clinical site for its ongoing pivotal Phase 3 clinical study in metastatic breast cancer [1][2] - The Phase 3 study now includes 69 active clinical sites across 15 states, enhancing the reach and potential patient enrollment for the trial [2] - The study evaluates BriaCell's lead candidate, Bria-IMT™, in combination with an immune checkpoint inhibitor against physician's choice in advanced metastatic breast cancer [3][4] Study Details - The primary endpoint of the study is overall survival (OS), with interim data analysis planned after 144 patient events (deaths) occur [4] - BriaCell has previously announced positive Phase 2 survival data for a similar patient population treated with the Bria-IMT combination regimen [4] - The Bria-IMT combination regimen has received FDA Fast Track designation, indicating its potential significance in cancer treatment [4] Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care [6]

Core Insights - Iovance Biotherapeutics, Inc. has appointed Corleen Roche as Chief Financial Officer, effective August 6, 2025, to support its first commercial launch and revenue growth [1][2][3] Company Overview - Iovance Biotherapeutics focuses on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients, aiming to be a global leader in this field [1][3] - The company has achieved FDA approval for its T cell therapy, Amtagvi, which is the first of its kind for a solid tumor indication [3] Leadership Experience - Corleen Roche brings over 30 years of experience in the biotech and life sciences industry, having held executive financial leadership roles in several publicly traded companies [2] - Roche's previous positions include CFO of CG Oncology, Immunome, and Biogen, where she successfully prepared for multiple product launches [2] Strategic Focus - The company aims to grow revenue, manage its balance sheet, and advance its mission of developing innovative therapies for solid tumors under Roche's financial leadership [2][3] - Roche expressed commitment to focusing pipeline investments on high-value opportunities while achieving financial goals to build a profitable biotechnology company [3]

FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD and type 2 diabetesFDA also confirmed that the ongoing Phase 3 PROACT 1 study can be used for both accelerated approval and for full approvalNearly half of the patients required for the accelerated approval analysis using eGFR slope have been enrolledTopline data to support an application for accelerated approval is anticipated in Q2 2027 WINSTON-SALEM, N.C., July 15, 2025 (GLOBE NE ...

Core Points - Emergent BioSolutions Inc. will host a conference call on August 6, 2025, at 5:00 pm eastern time to discuss its financial results for the second quarter of 2025 [1] - Participants can access the conference call via webcast or telephone, with advance registration required for telephone participation [2] - A replay of the conference call will be available on the Investors page of Emergent's website [3] Company Overview - Emergent BioSolutions has been dedicated to protecting and saving lives for over 25 years, focusing on public health preparedness [4] - The company provides life-saving solutions for various health threats, including smallpox, mpox, botulism, Ebola, anthrax, and opioid overdose emergencies [4]

China was once notorious for knockoff drugs, but the country’s biotech companies are advancing ferociously, eclipsing the EU and catching up to the US.@AmberTongPW looks at how Chinese drugmakers are challenging Western dominance on innovation https://t.co/0N3s5ude99 https://t.co/hibHYj5scH ...

The Unlikely Path From Iranian Revolution To Billionaire Biotech CEO https://t.co/z75ndwfzGF https://t.co/z75ndwfzGF ...

Investment Rating - The report upgrades the S&P 500 valuation and return forecasts, expecting a rise of 10% to 6900 over the next 12 months, with a forward P/E multiple of 22x [3][4]. Core Insights - The S&P 500 forward P/E of 22x ranks in the 97th percentile since 1980, but is deemed appropriate given the current macroeconomic conditions, including declining interest rates and elevated corporate profitability [3][11][12]. - Earnings growth is projected at 7% for both 2025 and 2026, with EPS estimates of $262 and $280 respectively, although there are two-way risks around these forecasts [6][24]. - The report highlights narrow market breadth, with the median S&P 500 constituent 11% below its high, indicating potential for a momentum reversal in the equity market [30][34]. - Sector allocation recommendations include a mix of secular growth (Software & Services, Media & Entertainment), cyclical (Materials), and defensive (Utilities, Real Estate) industries, with a focus on AI-related technology stocks [41][44]. Summary by Sections Valuation and Earnings Forecasts - The S&P 500 is expected to reach 6900 in 12 months, with return forecasts of +2%, +5%, and +10% over 3, 6, and 12 months respectively [4][47]. - The forward P/E multiple has been increased to 22x, with EPS growth of 7% anticipated for 2025 and 2026 [6][49]. Market Conditions - Current macroeconomic conditions support the elevated P/E multiple, with expectations of earlier Fed easing and lower bond yields [12][16]. - The report notes that investor positioning is neutral, suggesting that current market multiples do not reflect investor exuberance [17][20]. Sector Preferences - There is no clear consensus on sector preferences among clients, but AI-related technology stocks are generally favored despite valuation concerns [41][44]. - The recommendation to invest in Alternative Asset Managers within the Financials sector has been positively received [41]. Market Breadth and Momentum - The S&P 500's recent record high contrasts with the median constituent being significantly below its peak, indicating narrow market breadth [30][34]. - A potential momentum rotation is anticipated, although it is expected to be short-lived rather than indicative of a new long-term trend [40].

10 July 2025 China Pharma and Biotech China Pharma & Biotech: recent rally, multiple expansions, and where we still see opportunities Rebecca Liang, Ph.D. +852 2123 2656 rebecca.liang@bernsteinsg.com Haopeng Zhou +852 2123 2630 haopeng.zhou@bernsteinsg.com William Pickering, MD +1 917 344 8340 william.pickering@bernsteinsg.com Louisa Qiu +1 917 344 8495 louisa.qiu@bernsteinsg.com Will the pharma / biotech rally go on? China healthcare is having the strongest rally since mid-2023. Hang Sang Biotech and MSCI ...